SKYE · Skye Bioscience, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $42.36M | $18.70M | $6.01M | $6.01M | $2.93M | $1.94M |
| SG&A | $15.80M | $17.73M | $7.85M | $6.09M | $4.92M | $4.34M |
| Total Operating Expenses | $58.16M | $30.19M | $34.74M | $18.31M | $7.85M | $6.29M |
| D&A | $723.4K | $298.6K | $124.3K | $115.0K | $34.1K | $1.9K |
| Operating Income | ($58.16M) | ($30.19M) | ($34.74M) | ($18.31M) | ($7.85M) | ($6.29M) |
| Interest Expense | $0 | $749.3K | $906.3K | $665.1K | $769.2K | $706.4K |
| Income Tax | $5.4K | $10.1K | $3.6K | $6.7K | $2.1K | $1.6K |
| Net Income | ($55.92M) | ($26.57M) | ($37.64M) | ($19.48M) | ($8.52M) | ($6.56M) |
| EPS - Basic | ($1.41) | ($0.73) | ($5.37) | ($10.00) | ($5.00) | ($7.50) |
| EPS - Diluted | ($1.41) | ($0.73) | ($5.37) | ($10.00) | ($5.00) | ($7.50) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.88M | $68.42M | $10.34M | $1.25M | $8.99M | $2.47M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.03M | - | - | $1.67M | $897.9K | $364.3K |
| Current Assets | $27.09M | $70.83M | $11.65M | $8.94M | $9.61M | $2.66M |
| Total Assets | $28.31M | $72.76M | $11.94M | $9.11M | $9.86M | $2.67M |
| Current Liabilities | $8.21M | $4.34M | $13.90M | $12.12M | $3.91M | $787.2K |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $8.29M | $4.61M | $14.07M | $12.12M | $3.99M | $2.22M |
| Stockholders' Equity | $20.02M | $68.15M | ($2.13M) | ($3.01M) | $5.86M | $450.8K |
| Retained Earnings | ($186.87M) | ($130.95M) | ($104.38M) | ($66.74M) | ($47.26M) | ($38.73M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($43.06M) | ($25.24M) | ($13.95M) | ($12.74M) | ($6.47M) | ($6.05M) |
| Investing Cash Flow | ($19.50M) | ($245.6K) | $6.60M | $5.21M | ($90.9K) | ($7.2K) |
| Financing Cash Flow | $29.6K | $83.56M | $16.44M | ($208.8K) | $13.08M | $6.70M |
| CapEx | $6.3K | $1.60M | $12.6K | $28.1K | $90.9K | $7.2K |
| Free Cash Flow | ($43.07M) | ($26.84M) | ($13.96M) | ($12.77M) | ($6.57M) | ($6.06M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.77 | 1.01 | 0.37 | 0.66 | 0.77 | 0.92 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -197.5% | -36.5% | -315.3% | -213.8% | -86.5% | -245.6% |
| Return on equity | -279.3% | -39.0% | 1765.9% | 647.6% | -145.3% | -1455.4% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.30 | 16.32 | 0.84 | 0.74 | 2.46 | 3.38 |
| Quick ratio | 3.30 | 16.32 | 0.84 | 0.74 | 2.46 | 3.38 |
| Cash ratio | 0.72 | 15.77 | 0.74 | 0.10 | 2.30 | 3.14 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -40.3x | -38.3x | -27.5x | -10.2x | -8.9x |
| Equity multiplier | 1.41 | 1.07 | -5.60 | -3.03 | 1.68 | 5.93 |
| Liabilities / Assets | 0.29 | 0.06 | 1.18 | 1.33 | 0.40 | 0.83 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 1.5x | 1.5x | - | - | 901.4x | 5133.7x |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -92.6% | 13.1% | -89.7% | -133.3% | -24.8% | 5.2% |
| Net income growth (YoY) | -110.5% | 29.4% | -93.2% | -128.6% | -29.9% | - |
| EPS growth (YoY) | -93.2% | 86.4% | 46.3% | -100.0% | 33.3% | -4587.5% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -60.5% | -92.2% | -9.3% | -94.5% | -8.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -70.6% | - | 29.1% | - | 1200.9% | -17.7% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Skye Bioscience against the 5 most active filers in the same SIC group.